• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection.

作者信息

Takahashi Kanae, Yanagi Teruki, Kitamura Shinya, Hata Hiroo, Imafuku Keisuke, Iwami Daiki, Hotta Kiyohiko, Morita Ken, Shinohara Nobuo, Shimizu Hiroshi

机构信息

Departments of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

出版信息

J Dermatol. 2018 May;45(5):e116-e117. doi: 10.1111/1346-8138.14144. Epub 2017 Nov 23.

DOI:10.1111/1346-8138.14144
PMID:29168221
Abstract
摘要

相似文献

1
Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection.利妥昔单抗成功治疗一名患有特发性腕跗骨溶解症和慢性活动性抗体介导排斥反应的化脓性汗腺炎患者。
J Dermatol. 2018 May;45(5):e116-e117. doi: 10.1111/1346-8138.14144. Epub 2017 Nov 23.
2
Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.利妥昔单抗单药治疗肾移植后慢性活动性抗体介导的排斥反应。
Transpl Int. 2018 Apr;31(4):451-455. doi: 10.1111/tri.13111. Epub 2018 Jan 30.
3
Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.接受静脉注射免疫球蛋白和利妥昔单抗治疗的伴有持续性肾小管周围毛细血管炎的慢性抗体介导排斥反应患者的长期移植物存活情况。
Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13037. Epub 2017 Jul 13.
4
Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.肾移植受者中早期与晚期急性抗体介导排斥反应对利妥昔单抗治疗的反应：单中心经验
Exp Clin Transplant. 2017 Feb;15(Suppl 1):150-155. doi: 10.6002/ect.mesot2016.P32.
5
Diagnosis and management of hidradenitis suppurativa in women.女性化脓性汗腺炎的诊断与治疗。
Am J Obstet Gynecol. 2021 Jan;224(1):54-61. doi: 10.1016/j.ajog.2020.09.036. Epub 2020 Sep 24.
6
Efficient B cell Depletion With Rituximab Despite Massive Proteinuria.尽管存在大量蛋白尿，利妥昔单抗仍能有效清除B细胞。
Transplantation. 2018 Oct;102(10):e401-e402. doi: 10.1097/TP.0000000000002352.
7
Development of antibody mediated rejection shortly after acute cellular rejection in a pediatric kidney transplantation recipient.一名小儿肾移植受者在急性细胞排斥反应后不久发生抗体介导的排斥反应。
CEN Case Rep. 2018 Nov;7(2):288-291. doi: 10.1007/s13730-018-0344-z. Epub 2018 Jun 12.
8
The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.前沿。用阿达木单抗治疗重度化脓性汗腺炎。
Arch Dermatol. 2006 Sep;142(9):1110-2. doi: 10.1001/archderm.142.9.1110.
9
A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection.利妥昔单抗用于治疗抗体介导的肾移植排斥反应的系统评价。
Transplant Rev (Orlando). 2017 Apr;31(2):87-95. doi: 10.1016/j.trre.2017.01.002. Epub 2017 Jan 24.
10
Diagnosing Hidradenitis Suppurativa.化脓性汗腺炎的诊断
Dermatol Clin. 2016 Jan;34(1):1-5. doi: 10.1016/j.det.2015.08.009.

引用本文的文献

1
The Role of Cutaneous B-Cells in Hidradenitis Suppurativa: From Preclinical Evidence to Novel Targeted Therapies.皮肤B细胞在化脓性汗腺炎中的作用：从临床前证据到新型靶向治疗
Exp Dermatol. 2025 Sep;34(9):e70163. doi: 10.1111/exd.70163.
2
Skin Deep and Beyond: Unravelling B Cell Extracellular Matrix Interactions in Cutaneous Immunity and Disease.深入皮肤及其他方面：解析B细胞在皮肤免疫与疾病中的细胞外基质相互作用
Exp Dermatol. 2025 Mar;34(3):e70068. doi: 10.1111/exd.70068.
3
Serum Immunoglobulin G Levels and Nicastrin Variation in Hidradenitis Suppurativa.
化脓性汗腺炎患者的血清免疫球蛋白G水平及Nicastrin变异
JAMA Dermatol. 2025 Apr 1;161(4):411-415. doi: 10.1001/jamadermatol.2024.5684.
4
Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives.化脓性汗腺炎要点：诊断与治疗观点的全面综述
Ann Med Surg (Lond). 2024 Jul 1;86(9):5304-5313. doi: 10.1097/MS9.0000000000002345. eCollection 2024 Sep.
5
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa.三级淋巴结构维持化脓性汗腺炎皮肤 B 细胞的活性。
JCI Insight. 2024 Feb 8;9(3):e169870. doi: 10.1172/jci.insight.169870.
6
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.化脓性汗腺炎的转录组分析：具有广泛免疫激活的独特分子特征。
Int J Mol Sci. 2023 Nov 30;24(23):17014. doi: 10.3390/ijms242317014.
7
Transcriptome Meta-Analysis Confirms the Hidradenitis Suppurativa Pathogenic Triad: Upregulated Inflammation, Altered Epithelial Organization, and Dysregulated Metabolic Signaling.转录组元分析证实了化脓性汗腺炎的发病三联征：炎症上调、上皮组织改变和代谢信号失调。
Biomolecules. 2022 Sep 25;12(10):1371. doi: 10.3390/biom12101371.
8
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
9
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
10
Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling.化脓性汗腺炎分子发病机制的研究进展：角蛋白和细胞外基质信号失调。
Semin Cell Dev Biol. 2022 Aug;128:120-129. doi: 10.1016/j.semcdb.2022.01.006. Epub 2022 Feb 4.